Clinical Spectrum of Sarcoma in the Sultanate of Oman.

Q3 Medicine
The gulf journal of oncology Pub Date : 2025-05-01
Maitha Al Sibani, Ajit Venniyoor, Kawther Al Lawati, Ahmed AlLawati, Maryam Al Nabhani
{"title":"Clinical Spectrum of Sarcoma in the Sultanate of Oman.","authors":"Maitha Al Sibani, Ajit Venniyoor, Kawther Al Lawati, Ahmed AlLawati, Maryam Al Nabhani","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Sarcomas are a group of malignant tumors arising from mesenchymal tissue, with variable presentations and outcomes. Multiple factors contribute to the prognosis of the disease. As they are relatively infrequent, data on their clinical spectra and treatment outcomes are limited. The aim of this study is to identify the clinical spectrum of sarcomas in the Sultanate of Oman.</p><p><strong>Methods: </strong>This is a single-center, retrospective study, conducted in The Royal Hospital, Muscat. The target population was sarcoma patients aged 18 years and above, who were diagnosed and treated over 5 years between 2016 to 2020 in this hospital.</p><p><strong>Results: </strong>A total of 234 patients with histologically proven soft tissue and bone sarcomas were included in the study. The median age of the patients was 43 years. Soft tissue sarcomas (STS) constituted the most common type (72.2%). The most common histopathologic subtype of STS was uterine sarcoma at 25.8%, followed by gastrointestinal stromal tumors (GIST) (12.4%). Among 234 patients, 60 patients had metastatic disease and received palliative chemotherapy, and 174 patients were treated with curative intent. The mean progression free survival (PFS) in localized and metastatic bone sarcomas was 52.0 months and 10 months respectively. In STS cohort, the mean PFS in localized and metastatic was 33.0 months and 23.0 respectively. The mean of overall survival (OS) was 58.8 months and 11.8 months in localized and metastatic bone sarcomas while in STS, the mean of OS was 91.0 months and 26.0 months respectively. There was a statistically significant association between age and survival in STS, while the same was not seen in bone sarcomas.</p><p><strong>Conclusion: </strong>Sarcomas are infrequent tumors with variety of histological subtypes and prognosis. We observed a gradual decline in survival with advancing age in the STS group.</p>","PeriodicalId":53633,"journal":{"name":"The gulf journal of oncology","volume":"1 48","pages":"53-59"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The gulf journal of oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Sarcomas are a group of malignant tumors arising from mesenchymal tissue, with variable presentations and outcomes. Multiple factors contribute to the prognosis of the disease. As they are relatively infrequent, data on their clinical spectra and treatment outcomes are limited. The aim of this study is to identify the clinical spectrum of sarcomas in the Sultanate of Oman.

Methods: This is a single-center, retrospective study, conducted in The Royal Hospital, Muscat. The target population was sarcoma patients aged 18 years and above, who were diagnosed and treated over 5 years between 2016 to 2020 in this hospital.

Results: A total of 234 patients with histologically proven soft tissue and bone sarcomas were included in the study. The median age of the patients was 43 years. Soft tissue sarcomas (STS) constituted the most common type (72.2%). The most common histopathologic subtype of STS was uterine sarcoma at 25.8%, followed by gastrointestinal stromal tumors (GIST) (12.4%). Among 234 patients, 60 patients had metastatic disease and received palliative chemotherapy, and 174 patients were treated with curative intent. The mean progression free survival (PFS) in localized and metastatic bone sarcomas was 52.0 months and 10 months respectively. In STS cohort, the mean PFS in localized and metastatic was 33.0 months and 23.0 respectively. The mean of overall survival (OS) was 58.8 months and 11.8 months in localized and metastatic bone sarcomas while in STS, the mean of OS was 91.0 months and 26.0 months respectively. There was a statistically significant association between age and survival in STS, while the same was not seen in bone sarcomas.

Conclusion: Sarcomas are infrequent tumors with variety of histological subtypes and prognosis. We observed a gradual decline in survival with advancing age in the STS group.

阿曼苏丹国肉瘤的临床谱。
肉瘤是一组起源于间质组织的恶性肿瘤,具有不同的表现和预后。多种因素影响疾病的预后。由于它们相对不常见,有关其临床谱和治疗结果的数据有限。本研究的目的是确定在阿曼苏丹国肉瘤的临床谱。方法:这是一项在马斯喀特皇家医院进行的单中心回顾性研究。目标人群为2016年至2020年在本院诊疗5年以上的18岁及以上肉瘤患者。结果:共有234例组织学证实的软组织和骨肉瘤患者纳入研究。患者的中位年龄为43岁。软组织肉瘤(STS)是最常见的类型(72.2%)。STS最常见的组织病理学亚型是子宫肉瘤(25.8%),其次是胃肠道间质瘤(GIST)(12.4%)。在234例患者中,60例患者有转移性疾病并接受了姑息性化疗,174例患者的治疗目的是治愈。局部骨肉瘤和转移性骨肉瘤的平均无进展生存期(PFS)分别为52.0个月和10个月。在STS队列中,局部和转移的平均PFS分别为33.0个月和23.0个月。局限性骨肉瘤和转移性骨肉瘤的平均总生存期(OS)分别为58.8个月和11.8个月,而STS的平均总生存期分别为91.0个月和26.0个月。STS患者的年龄与生存率有统计学意义的相关性,而骨肉瘤患者的年龄与生存率无统计学意义的相关性。结论:肉瘤是一种少见的肿瘤,组织学亚型多样,预后良好。我们观察到STS组的生存率随着年龄的增长而逐渐下降。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
The gulf journal of oncology
The gulf journal of oncology Medicine-Medicine (all)
CiteScore
0.90
自引率
0.00%
发文量
37
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书